August 17, 2018
Facilitating Drug Discovery with 3D In Vitro Oncology Models
Around 95% of new anticancer drugs eventually fail in clinical trials, despite promising results when tested on 2D in vitro preclinical models. New models that better mimic tumor biology in vivo can facilitate more efficient and translatable drug discovery research.
LEARN MORE
July 26, 2018
IDO to I DON’T – IDO1 Inhibitor Development News
As targeted immuno-oncology agents make impressive strides in cancer treatment, researchers are looking for agents that ...
LEARN MORE
July 5, 2018
Personalized Cancer Immunotherapy
Precision medicine and immunotherapy are currently two of the hottest areas of cancer research. How can immuno-oncology ...
LEARN MORE
July 3, 2018
Custom Murine Tumor Homografts for Efficacy Assessment
Murine tumor homografts provide an immunotherapeutic efficacy testing platform with the strengths of GEMM paired with ...
LEARN MORE
June 28, 2018
Assessing Combination Therapies in Syngeneic Tumor Models
Combination immunotherapy could enhance the clinical benefits of monotherapies and overcome patient lack of response to ...
LEARN MORE
June 26, 2018
Why to Use Isotype Control Antibodies
Good experimental design is key to accurate and precise drug development. Isotype control antibodies, designed and ...
LEARN MORE
June 21, 2018
Immunocompetent Murine Models for Immunotherapy Assessment
Immunocompetent models are necessary for the preclinical assessment of novel immunotherapies, but multiple murine model platforms are available for the evaluation of cross reactive and surrogate agents. Here we look at syngeneics, GEMM, and murine tumor homograft models and how to choose the best model for your immuno-oncology study.
LEARN MORE
June 12, 2018
Leveraging PDX Models for In Vitro and Ex Vivo Assays
Patient-derived xenografts (PDX) are the most predictive and translational xenograft models available for preclinical ...
LEARN MORE
June 5, 2018
PDX and Personalized Medicine
We discussed patient-derived xenografts (PDX) previously, from how to establish the models to when to add them to ...
LEARN MORE
May 31, 2018
Predictive Immuno-Oncology Studies with Humanized PDX
Patient-derived xenograft (PDX) models are typically immunodeficient and inappropriate for most immuno-oncology (I/O) ...
LEARN MORE
May 29, 2018
Webinar FAQ: PDX Models in Drug Discovery Assays
Patient-derived xenografts (PDX) are the most predictive and translational preclinical xenograft models available for oncology research. Novel platforms are expanding their use into in vitro and ex vivo drug discovery assays, opening new applications for PDX throughout the preclinical drug discovery pipeline.
LEARN MORE
May 24, 2018
Webinar FAQ: Humanized PDX Models in Immuno-Oncology
Patient-derived xenografts (PDX) support highly translational preclinical oncology research, but were historically ...
LEARN MORE
May 22, 2018
Immuno-Oncology and the Microbiome at AACR 2018
CrownBio presented thirteen posters at AACR 2018, sharing our latest internal research into patient derived xenografts, ...
LEARN MORE
May 17, 2018
Genetically Engineered or Syngeneic Mouse Models?
Mouse models are a mainstay of preclinical cancer research, and immunocompetent model use is rising with continued ...
LEARN MORE
May 15, 2018
Murine Homograft Tumor Models at AACR 2018
We presented a wide range of immuno-oncology model data at AACR 2018, with three of our thirteen posters covering our ...
LEARN MORE
